Histone deacetylase inhibitors: Anticancer compounds

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 1, 2009, Pages 21-25

  Smith, Karen T ^a   Workman, Jerry L ^a  

^a STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Acetylation; Cancer; Cell cycle; Chromatin; HDAC

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ACETIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; APICIDIN; BELINOSTAT; BUTYRIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEPSIPEPTIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; RETINOIC ACID; ROMIDEPSIN; SODIUM PHENYLBUTYRATE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; APOPTOSIS; CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; EPIGENETICS; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN STABILITY; SHORT SURVEY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 55949083044     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.09.008     Document Type: Short Survey

References (49)

1. Alao J.P., Lam E.W., Ali S., Buluwela L., Bordogna W., Lockey P., et al. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 10 (2004) 8094-8104
2. Bokelmann I., and Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 14 1-2 (2008) 20-27
3. Dokmanovic M., Perez G., Xu W., Ngo L., Clarke C., Parmigiani R.B., et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 6 9 (2007) 2525-2534
4. Fenrick R., and Hiebert S.W. Role of histone deacetylases in acute leukemia. J Cell Biochem Suppl 30-31 (1998) 194-202
5. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 6749 (1999) 188-193
6. Glaser K.B., Li J., Staver M.J., Wei R.Q., Albert D.H., and Davidsen S.K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310 (2003) 529-536
7. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., and Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2 (2003) 151-163
8. Glozak M.A., Sengupta N., Zhang X., and Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363 (2005) 15-23
9. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 24 (2001) 6969-6978
10. Hahn C.K., Ross K.N., Warrington I.M., Mazitschek R., Kanegai C.M., Wright R.D., et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci USA 105 28 (2008) 9751-9756
11. Hodawadekar S.C., and Marmorstein R. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26 37 (2007) 5528-5540
12. Hu J., and Colburn N.H. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 3 2 (2005) 100-109
13. Im J.Y., Park H., Kang K.W., Choi W.S., and Kim H.S. Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem Biol Interact 172 3 (2008) 235-244
14. Joseph J., Mudduluru G., Antony S., Vashistha S., Ajitkumar P., and Somasundaram K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23 37 (2004) 6304-6315
15. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 17 (2005) 3923-3931
16. Kim Y.B., Lee K.H., Sugita K., Yoshida M., and Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18 15 (1999) 2461-2470
17. Kim S.H., Jeong J.W., Park J.A., Lee J.W., Seo J.H., Jung B.K., et al. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 17 3 (2007) 647-651
18. Komatsu N., Kawamata N., Takeuchi S., Yin D., Chien W., Miller C.W., et al. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 15 1 (2006) 187-191
19. Kramer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A., et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22 13 (2003) 3411-3420
20. Kramer O.H., Muller S., Buchwald M., Reichardt S., and Heinzel T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. FASEB J 22 5 (2008) 1369-1379
21. Kumagai T., Wakimoto N., Yin D., Gery S., Kawamata N., Takai N., et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121 3 (2007) 656-665
22. Lallemand F., Courilleau D., Sabbah M., Redeuilh G., and Mester J. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate. Biochem Biophys Res Commun 229 1 (1996) 163-169
23. Lin Y.C., Lin J.H., Chou C.W., Chang Y.F., Yeh S.H., and Chen C.C. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 68 7 (2008) 2375-2383
24. Lindemann R.K., Newbold A., Whitecross K.F., Cluse L.A., Frew A.J., Ellis L., et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 104 19 (2007) 8071-8076
25. Mann B.S., Johnson J.R., Cohen M.H., Justice R., and Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 10 (2007) 1247-1252
26. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 26 9 (2007) 1351-1356
27. Martinez-Balbas M.A., Bauer U.M., Nielsen S.J., Brehm A., and Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 19 4 (2000) 662-671
28. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
29. Munshi A., Kurland J.F., Nishikawa T., Tanaka T., Hobbs M.L., Tucker S.L., et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11 13 (2005) 4912-4922
30. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 10 (2005) 3697-3702
31. Petrella A., D'Acunto C.W., Rodriquez M., Festa M., Tosco A., Bruno I., et al. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur J Cancer 44 5 (2008) 740-749
32. Qian D.Z., Kachhap S.K., Collis S.J., Verheul H.M., Carducci M.A., Atadja P., et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66 17 (2006) 8814-8821
33. Qiu Y., Zhao Y., Becker M., John S., Parekh B.S., Huang S., et al. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol Cell 22 5 (2006) 669-679
34. Reid G., Metivier R., Lin C.Y., Denger S., Ibberson D., Ivacevic T., et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 24 (2005) 4894-4907
35. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97 18 (2000) 10014-10019
36. Ropero S., Fraga M.F., Ballestar E., Hamelin R., Yamamoto H., Boix-Chornet M., et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38 (2006) 566-569
37. Schuetz A., Min J., Allali-Hassani A., Schapira M., Shuen M., Loppnau P., et al. Human HDAC7 Harbors a Class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem 283 17 (2008) 11355-11363
38. Scott G.K., Mattie M.D., Berger C.E., Benz S.C., and Benz C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66 3 (2006) 1277-1281
39. Sekhavat A., Sun J.M., and Davie J.R. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem Cell Biol 85 6 (2007) 751-758
40. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101 42 (2004) 15064-15069
41. Villa R., Morey L., Raker V.A., Buschbeck M., Gutierrez A., De Santis F., et al. The methyl-CpG binding protein MBD1 is required for PML-RARalpha function. Proc Natl Acad Sci USA 103 5 (2006) 1400-1405
42. Vrana J.A., Decker R.H., Johnson C.R., Wang Z., Jarvis W.D., Richon V.M., et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18 50 (1999) 7016-7025
43. Warrell Jr. R.P., He L.Z., Richon V., Calleja E., and Pandolfi P.P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90 21 (1998) 1621-1625
44. Wu L.P., Wang X., Li L., Zhao Y., Lu S., Yu Y., et al. HDAC inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol (2008)
45. Xiong Y., Dowdy S.C., Podratz K.C., Jin F., Attewell J.R., Eberhardt N.L., et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res 65 7 (2005) 2684-2689
46. You J.S., Kang J.K., Lee E.K., Lee J.C., Lee S.H., Jeon Y.J., et al. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 27 10 (2008) 1376-1386
47. Zhao Y., Tan J., Zhuang L., Jiang X., Liu E.T., and Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102 44 (2005) 16090-16095
48. Zhao Y., Lu S., Wu L., Chai G., Wang H., Chen Y., et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26 7 (2006) 2782-2790
49. Zhou Q., Agoston A.T., Atadja P., Nelson W.G., and Davidson N.E. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 6 5 (2008) 873-883